[DOI] [PMC free article] [PubMed] [Google Scholar] 76.Prasad-Reddy L, Isaacs D
Drivers : Strong growth of private label and OEM services for brands
DO NOT use em-dashes () or en-dashes (): Use regular hyphens (-) only Return ONLY the edited section content with no explanations, no preamble, no markdown code fences If you cannot find the exact sentence, find the closest match and replace it Do not add any commentary or notes The output should be pure article text that can be directly inserted CRITICAL: If the replacement text contains line breaks (blank lines between sentences), you MUST preserve those line breaks in your output
A review of Diabetic Gastroparesis found that the class of drugs known as glucagon-like peptide 1 (GLP-1) receptor agonists such as dulaglutide (Trulicity) may exacerbate the symptoms of diabetic gastroparesis and therefore are not recommended for individuals experiencing symptoms of gastroparesis
GLP-1 and Incretin-Based Peptides Semaglutide Semaglutide is a GLP-1 receptor agonist that mimics the incretin hormone to regulate appetite signaling and metabolic pathways
Being on this list means: Athletes are not required to declare GLP-1 use No Therapeutic Use Exemption (TUE) is needed It is legal to use before, during, and after competition WADA is collecting prevalence data through anonymous sample analysis A substance can remain on the monitoring list for years before any decision is made Historically, substances spend 2-5 years on the monitoring program before WADA decides to either ban them or remove them from monitoring
